<DOC>
	<DOCNO>NCT01140997</DOCNO>
	<brief_summary>This study multi-center , randomize , open-label positive control Phase II Clinical trial ass efficacy safety Ypeginterferon alfa-2b ( Ribavirin ) , week , 3 dose-groups respectively , treatment Chronic Hepatitis C patient , Pegasys 180mcg/week &amp; Ribavirin positive control . It aim establish dose response safety relationship sufficient allow subsequent design conduct Phase III trial , generate PK data hepatitis C patient satisfy regulatory requirement .</brief_summary>
	<brief_title>Efficacy Safety Ypeginterferon Alfa-2b Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age : 18~65 year . Pregnancy test female patient must negative . All patient effective birth control measure treatment period 6 month cessation treatment . Chronic HCV infection evidence : HCV RNA antiHCV positive &gt; 6 month ; liver biopsy evidence ; vital sign , symptom , exposure history , result laboratory test iconography examination support diagnosis chronic hepatitis C. HCV RNAâ‰¥2000IU/ml . Pregnant lactate woman . Mental disorder physical disability . WBC &lt; 3000/mm3 , ANC &lt; 1500/mm3 , PLT &lt; 90,000/mm3 . Received interferon treatment within previous 6 month shew response interferon . Coinfection HIV , HAV , HBV , HEV . Evidence hepatic decompensation . Chest Xray clinically significant active inflammatory process , history significant pulmonary disease history interstitial lung disease . History hypothyroidism current treatment thyroid disease . Diabetes mellitus . Uncontrolled significant chronic medical condition chronic hepatitis C condition opinion investigator preclude enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>HCV</keyword>
	<keyword>CHC</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Hepatitis , Chronic</keyword>
	<keyword>Hepatitis , Viral , Human</keyword>
	<keyword>Hepadnaviridae Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Peginterferon alfa</keyword>
</DOC>